Immunopathy of lung cancer , lung cancer immunotherapy method , lung cancer immunotherapy drug

Immunopathy of lung cancer , lung cancer immunotherapy method , lung cancer immunotherapy drug

Immunogenic detection point (PD-L1 / PD-1) inhibitor

    The immunological examination point is a type of immunosuppressive molecule to avoid damage and damage of the autoimmune system, while tumor cells tend to use the characteristics of the immunoassay point, expressing molecules such as PD-L1, inhibiting the activity of cells.

    Treatment of drugs: Nawu combabell, Pasta anti-Atezolizumab

    The effect of effects affects:

    1. The positive expression of PD-L1 in tumor cells is the primary factor, and the expression of high treatment is good.

    2. Depending on the mutation burden or the NEoantigen Burden, the more tumor-specific new antigen can be produced by T cell recognition, and it is easy to identify the killing of T cells. Clinical manifestations of smoking and EGFR wild type patients better than the treatment of non-smoking patients.

vaccine

    In general, the lung cancer vaccine did not play the treatment effect.

    The most basic reason is that patients can give vaccines prior to infecting certain diseases to make the vaccine to play the best effect. For example, the ceiling vaccine is ineffective. Clinically, the treatment of lung cancer vaccine is the late patient with lung cancer.

Reference

1. Du L., ET Al. Immunotherapy in lung Cancer.Hematol Oncol Clin North AM.